Cureus · 2025
Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bizarro Rita, Pazos Isabel, Teixeira Alexandra, Pereira Margarida, Gonçalves Joana, Abreu Catarina, Ferreira Rita, Oliveira Sónia, Duarte Mendes Ana, Eiriz Inês, Santiago Mariana, Teixeira Carina, Leitão Maria, Guedes Helena, Bento Sandra, Inácio Mariana, Alpoim Tiago, Correia Jorge, Branco Francisco, Passos-Coelho José, Casa-Nova Mafalda, Teixeira José Alberto
Аннотация
BACKGROUND: Substantial improvements in survival have been observed in HER2 (human epidermal growth factor receptor 2)-positive (HER2+) inoperable or metastatic breast cancer (advanced breast cancer [ABC]) in recent years, driven by the introduction and widespread use of multiple novel agents. The DESTINY-Breast02 trial compared the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2+ ABC formerly treated with trastuzumab emtansine (T-DM1), demonstrating significant improvements in both overall survival (OS) and progression-free survival (PFS).
METHODS: We conducted a national, multicentric, retrospective study to describe real-world treatment patterns, PFS, OS, safety, and key toxicities associated with T-DXd use in Portugal, following the DESTINY-Breast02 inclusion criteria.
RESULTS: A total of 100 women with HER2+ ABC from 17 centers were included, all of whom had received at least two prior treatments for advanced disease and were treated with T-DXd between July 2021 and May 2023. The mean age was 53.9 years n(standard deviation: 9.9). Thirty-six patients presented with synchronous metastatic disease. The most common metastatic site was bone, in 61 (61%) patients; 72 (72%) had visceral metastases, and 21 patients (21%) had brain metastases. The median follow-up was 10 months, with a median of 11 T-DXd cycles administered. Prior treatments included pertuzumab in 71 (71%) patients and T-DM1 in 84 (84%). T-DXd was administered as third-line therapy in 52 (52%) patients, as fourth-line therapy in 15 (15%), and as fifth-line therapy and beyond in 23 (23%) patients. The overall response rate (ORR) was 44%, and the clinical benefit rate (CBR) was 80%. The most frequent toxicities of any grade were nausea in 49 patients (49%), neutropenia in 37 (37%), and alopecia in 34 (34%). Serious adverse events (grade ≥ 3) occurred in 16 (16%) patients, with treatment discontinuation or delays due to adverse events observed in 46 cases (46%). Median OS was not reached, with a 12-month OS rate of 74%. The median PFS was 13 months (95% CI: 10-16 months), and the 12-month PFS rate was 54%.
CONCLUSIONS: This real-world analysis revealed that the efficacy, safety, and tolerability of T-DXd in the Portuguese population are consistent with the outcomes observed in the DESTINY-Breast02 clinical trial.
METHODS: We conducted a national, multicentric, retrospective study to describe real-world treatment patterns, PFS, OS, safety, and key toxicities associated with T-DXd use in Portugal, following the DESTINY-Breast02 inclusion criteria.
RESULTS: A total of 100 women with HER2+ ABC from 17 centers were included, all of whom had received at least two prior treatments for advanced disease and were treated with T-DXd between July 2021 and May 2023. The mean age was 53.9 years n(standard deviation: 9.9). Thirty-six patients presented with synchronous metastatic disease. The most common metastatic site was bone, in 61 (61%) patients; 72 (72%) had visceral metastases, and 21 patients (21%) had brain metastases. The median follow-up was 10 months, with a median of 11 T-DXd cycles administered. Prior treatments included pertuzumab in 71 (71%) patients and T-DM1 in 84 (84%). T-DXd was administered as third-line therapy in 52 (52%) patients, as fourth-line therapy in 15 (15%), and as fifth-line therapy and beyond in 23 (23%) patients. The overall response rate (ORR) was 44%, and the clinical benefit rate (CBR) was 80%. The most frequent toxicities of any grade were nausea in 49 patients (49%), neutropenia in 37 (37%), and alopecia in 34 (34%). Serious adverse events (grade ≥ 3) occurred in 16 (16%) patients, with treatment discontinuation or delays due to adverse events observed in 46 cases (46%). Median OS was not reached, with a 12-month OS rate of 74%. The median PFS was 13 months (95% CI: 10-16 months), and the 12-month PFS rate was 54%.
CONCLUSIONS: This real-world analysis revealed that the efficacy, safety, and tolerability of T-DXd in the Portuguese population are consistent with the outcomes observed in the DESTINY-Breast02 clinical trial.